Journal of Neuroimmune Pharmacology

, Volume 6, Issue 1, pp 158–162

n-Dodecyl-β-d-Maltoside Inhibits Aggregation of Human Interferon-β-1b and Reduces Its Immunogenicity

Authors

    • Department of NeurologyThe Johns Hopkins University School of Medicine
  • Edward T. Maggio
    • Aegis Therapeutics, LLC
  • Sonny Dike
    • Department of NeurologyThe Johns Hopkins University School of Medicine
  • Douglas A. Kerr
    • Biogen Idec, Inc
  • Michael Levy
    • Department of NeurologyThe Johns Hopkins University School of Medicine
ORIGINAL ARTICLE

DOI: 10.1007/s11481-010-9226-7

Cite this article as:
Rifkin, R.A., Maggio, E.T., Dike, S. et al. J Neuroimmune Pharmacol (2011) 6: 158. doi:10.1007/s11481-010-9226-7

Abstract

The development of neutralizing antibodies to the protein drug interferon-β is a significant impediment to its use in the treatment of multiple sclerosis. Neutralizing antibodies to interferon-β arise from aggregation of the peptide during manufacturing and storage. We tested the ability of dodecylmaltoside, a nontoxic alkylsaccharide surfactant, to reduce aggregation of interferon-β in vitro and to reduce its immunogenicity in vivo. Interferon-β, in solution with and without dodecylmaltoside, was periodically evaluated for aggregation by light scatter for 1 month. Interferon-β, with and without dodecylmaltoside, was given 3 days/week for 1 month to mice; the sera of these mice were analyzed for anti-interferon-β antibodies by ELISA. Dodecylmaltoside reduces the aggregation of interferon-β in vitro and its immunogenicity in vivo. Our positive findings warrant additional tests of dodecylmaltoside as a therapeutic adjuvant in rodent models of multiple sclerosis.

Keywords

multiple sclerosisinterferon-betaexcipientsdisaccharides/chemistry

Copyright information

© Springer Science+Business Media, LLC 2010